Our Science

Abstracts and Publications

Select A2 Bio Scientific Publications

The End of an Era of Cancer Drug Discovery: Life Without New Drug Targets

Mardiros A, Kamb A. Immuno-oncology Insights: April 2022.

Robust In Vitro Pharmacology of Tmod, A Synthetic Dual-Signal Integrator for Cancer Cell Therapy

Manry D, Bolanos K, DiAndreth B, et al. Frontiers in Immunology: March 2022.

A Carcinoembryonic Antigen-specific Cell Therapy Selectively Targets Tumor Cells with HLA Loss of Heterozygosity in Vitro and In Vivo

Sandberg M, Wang X, Martin A, et al. Science Translational Medicine: March 2022.

VIEW ARTICLE

Chimeric Antigen Receptors Directed at Mutant KRAS Exhibit an Inverse Relationship Between Functional Potency and Neoantigen Selectivity

Tokatlian T, Asuelime G, Naradikian M, et al. Cancer Research Communications: January 2022.

VIEW ARTICLE

A Rational Approach to Assess Off-Target Reactivity of a Dual-Signal Integrator for T Cell Therapy

Wang X, Wong LM, McElvain M, et al. Toxicology and Applied Pharmacology: January 2022.

VIEW ARTICLE

Mesothelin-Specific CAR-T Cell Therapy that Incorporates an HLA-Gated Safety Mechanism Selectively Kills Tumor Cells

Tokatlian T, Asuelime G, Mock JY, et al. Journal of ImmunoTherapy for Cancer: January 2022.

VIEW ARTICLE

Potent, Selective CARs as Potential T-Cell Therapeutics for HPV-positive Cancers

Wang X, Sandberg M, Martin A, et al. Journal of Immunotherapy: October 2021.

VIEW ABSTRACT

Extensive Functional Comparisons Between Chimeric Antigen Receptors and T-cell Receptors Highlight Fundamental Similarities

Wang X, Martin A, Negri K, et al. Molecular Immunology: October 2021.

VIEW ABSTRACT

Design of TCR Structural Variants That Retain or Invert the Normal Activation Signal

Mock JY, Oh J, Yi J, et al. ImmunoHorizons: May 1, 2021.

VIEW ABSTRACT

Re-examination of MAGE-A3 as a T-cell Therapeutic Target

Martin A, Wang X, Sandberg M, et al. Journal of Immunotherapy: April 2021.

VIEW ARTICLE

HLA-A*02:01-directed Chimeric Antigen Receptor/Forkhead Box P3-engineered CD4+ T cells Adopt a Regulatory Phenotype and Suppress Established Graft-versus-host Disease

Martin A, Daris M, Johnston J, et al. Cytotherapy: February 2021.

V IEW ARTICLE

Engineered T-cells Directed at Tumors with Defined Allelic Loss

Hamburger A, DiAndreth B, Cui J, et al. Molecular Immunology: December 2020.

VIEW ARTICLE

A Multivariate, Quantitative Assay that Disentangles Key Kinetic Parameters of Primary Human T Cell Function In Vitro

Huang GL, Nampe DP, Yi J, et al. PLoS ONE: November 2020.

VIEW ARTICLE

Structure-function Relationships of Chimeric Antigen Receptors in Acute T-cell Responses to Antigen

Xu H, Hamburger A, Mock JY, et al. Molecular Immunology: October 2020.

VIEW ARTICLE

Cancer T-cell Therapy: Building the Foundation for a Cure

Kamb A, Go W. F1000 Research: November 2020.

VIEW ARTICLE

Single variable domains from the T cell receptor β chain function as mono- and bifunctional CARs and TCRs

Oh J, Warshaviak D, Mkrtichyan M, et al. Scientific Report: November 2019.

VIEW ARTICLE

A Powerful, Precise Targeting System Controlled by Tumor Deletions Transforms CEA and MSLN CAR-T Cells Into Tumor-Selective Agents

Hamburger A, Xu H, Ando Y, et al. Poster presentation at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC). November 2021.

VIEW POSTER

BASECAMP-1: An Observational Study to Identify Relapsed Solid Tumor Patients with Human Leukocyte Antigen (HLA) Loss of Heterozygosity (LOH) and Leukapheresis for Future CAR T Cell Therapy

Molina J, Go W, Kopetz S, et al. Poster presentation at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC). November 2021.

VIEW POSTER

A Computational Approach to Predict Off-target Peptide Selectivity of pMHC Targeting Therapeutics

Warshaviak D, Nampe D, Wang X, et al. Poster presentation at The Essential Protein Engineering & Cell Therapy Summit Virtual. August 2020.

VIEW POSTER

Julian Molina genetherapylive

Treating Solid Tumors With Personalized Immunotherapy: Julian Molina, MD, PhD

Molina J. Interview conducted at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC). November 2021.

VIEW INTERVIEW

Julian Molina genetherapylive

Improving Specificity of T-Cell Therapies in Solid Tumors: Julian Molina, MD, PhD

Molina J. Interview conducted at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC). November 2021.

VIEW INTERVIEW

Tmod™ T cell Therapy Platform Overview

Kamb, A. Interviews conducted at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC). November 2021.

VIEW INTERVIEW

BASECAMP-1: An Observational Study to Identify Relapsed Solid Tumor Patients with Human Leukocyte Antigen (HLA) Loss of Heterozygosity (LOH) and Leukapheresis for Future CAR T Cell Therapy

Molina J. Oral poster presentation at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC). November 2021.

VIEW PRESENTATION

Managing Clinical Safety and Toxicity for Improved Patient Outcomes

Go W. Oral presentation at CAR-TCR Summit 2021. August 2021.

VIEW PRESENTATION

Optimizing Efficiency in Trial Sponsor and Clinician Relationships

Geiger B, Matthews A, Melvin P, et al. Panel discussion at CAR-TCR Summit 2021. August 2021.

VIEW PRESENTATION

Next-generation Logic-gated Cell Therapy

Go W. Oral presentation at the International Workshop on CAR-T 2021. April 2021.

VIEW PRESENTATION

Engineered T Cells Directed at Tumors with Defined Allelic Loss

Hamburger A, DiAndreth B, Cui J, et al. Oral presentation at 3rd Cell Therapies and Immunotherapy Conference. October 2020.

VIEW PRESENTATION

Explore Our Pipeline